Novo Nordisk's CagriSema outperforms tirzepatide in weight loss trial for type 2 diabetes

In a late-stage trial, Novo Nordisk’s experimental drug CagriSema achieved greater weight reduction than tirzepatide at the 5 mg dose, signalling a potential breakthrough in diabetes and weight management treatments. Novo Nordisk said its experimental obesity drug CagriSema produced greater…















